US-based biopharmaceutical firm Esperion Therapeutics has dosed the first patient in its Phase II clinical trial of ETC-1002 to treat patients with hypercholesterolemia and hypertension, ETC-1002-014.
ETC-1002 is an orally available, once-daily small molecule designed to lower levels of LDL-cholesterol and to avoid side-effects associated with existing LDL-cholesterol lowering therapies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Around 144 patients are expected to be enrolled in the randomised, double-blind, parallel group, multicentre trial, which is evaluating parallel doses of ETC-1002 in these patients.
Top-line results from the Phase III trial are expected to be reported in the second quarter of 2015.
Esperion president and chief executive officer Tim Mayleben said: "Many patients with high LDL-cholesterol levels also have hypertension.
"This clinical study will help to further elucidate the LDL-cholesterol lowering efficacy, safety and tolerability profile of ETC-1002 in patients with both hypercholesterolemia and hypertension."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe primary objective of the trial is to evaluate the LDL-cholesterol lowering efficacy of ETC-1002 monotherapy versus placebo in patients with both hypercholesterolemia and hypertension who are treated for six weeks.
The trial’s secondary objectives include evaluating the effect of ETC-1002 on blood pressure, other lipid and cardiometabolic biomarkers and characterising the tolerability and safety of ETC-1002.
The dual mechanism of action in ETC-1002 helps in regulating both lipid and carbohydrate metabolism.
ETC-1002 works by inhibiting ATP citrate lyase (ACL), a key enzyme in the cholesterol biosynthetic pathway as well as activates a complementary enzyme, 5′-adenosine monophosphate-activated protein kinase (AMPK).
Both enzymes are said to play major roles in the synthesis of cholesterol and glucose in the liver.
According to the company, ETC-1002 inhibits cholesterol synthesis in the liver and causes the liver to take up LDL particles from the blood, which reduces LDL-cholesterol levels.
In seven completed Phase I and II clinical trials carried out in more than 300 patients, ETC-1002 had shown consistent and clinically meaningful reductions in LDL-cholesterol, as well as reductions in levels of high sensitivity C-reactive protein (hsCRP), a key marker of inflammation associated with cardiovascular disease.
The company is focused on developing and commercialising first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.
